148 Chapter 6 64. McKINNELL JA, Kunz DF, Moser SA et al. Patient-level analysis of incident vancomycinresistant enterococci colonization and antibiotic days of therapy. Epidemiol Infect 2016; 144: 1748–55. 65. King ST, Barber KE, Parham JJ et al. Shifts in antimicrobial consumption and infection rates before and during a piperacillin/tazobactam shortage. J Glob Antimicrob Re 2017; 11: 111–3. 66. Richards DM, Heel RC, Brogden RN et al. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 1984; 27: 469–527. 67. Welling GW, Meijer-Severs GJ, Helmus G et al. The effect of ceftriaxone on the anaerobic bacterial flora and the bacterial enzymatic activity in the intestinal tract. Infection 1991; 19: 313–6. 68. de Vries-Hospers HG, Tonk RH, van der Waaij D. Effect of intramuscular ceftriaxone on aerobic oral and faecal flora of 11 healthy volunteers. Scand J Infect Dis 1991; 23: 625–33. 69. Cavallaro V, Catania V, Bonaccorso R et al. Effect of a broad-spectrum cephalosporin on the oral and intestinal microflora in patients undergoing colorectal surgery. J Chemotherapy 1992; 4: 82–7. 70. Vogel F, Ochs HR, Wettich K et al. Effect of step-down therapy of ceftriaxone plus loracarbef versus parenteral therapy of ceftriaxone on the intestinal microflora in patients with community-acquired pneumonia. Clin Microbiol Infec 2001; 7: 376–9. 71. Nilsson-Ehle I, Nord CE, Ursing B. Ceftriaxone: pharmacokinetics and effect on the intestinal microflora in patients with acute bacterial infections. Scand J Infect Dis 1985; 17: 77–82. 72. Lambert-Zechovsky N, Bingen E, Aujard Y et al. Impact of cefotaxime on the fecal flora in children. Infection 1985; 13 Suppl 1: S140-144. 73. de Lastours V, Goulenok T, Guérin F et al. Ceftriaxone promotes the emergence of AmpCoverproducing Enterobacteriaceae in gut microbiota from hospitalized patients. Eur J Clin Microbiol 2018; 37: 417–21. 74. Meletiadis J, Turlej-Rogacka A, Lerner A et al. Amplification of antimicrobial resistance in gut flora of patients treated with ceftriaxone. Antimicrob Agents Ch 2017; 61: e00473-17. 75. Baggs J, Fridkin SK, Pollack LA et al. Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012. JAMA Intern Med 2016; 176: 1639–48. 76. Wendt C, Lin D, von Baum H. Risk factors for colonization with third-generation cephalosporin-resistant enterobacteriaceae. Infection 2005; 33: 327–32. 77. Guggenbichler JP, Kofler J, Allerberger F. The influence of third-generation cephalosporins on the aerobic intestinal flora. Infection 1985; 13 Suppl 1: S137-139. 78. Crew PE, Rhodes NJ, O’Donnell JN et al. Correlation between hospital-level antibiotic consumption and incident health care facility-onset Clostridium difficile infection. Am J Infect Control 2018; 46: 270–5. 79. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemoth 2014; 69: 881–91. 80. McKinnell JA, Kunz DF, Chamot E et al. Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage. Infect Cont Hosp Ep 2012; 33: 718–24. 81. Bergan T, Nord CE, Thorsteinsson SB. Effect of meropenem on the intestinal microflora. Eur J Clin Microbiol 1991; 10: 524–7. 82. Norrby SR, Rogers JD, Ferber F et al. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Ch 1984; 26: 707–14. 83. Kager L, Brismar B, Malmborg AS et al. Imipenem concentrations in colorectal surgery and impact on the colonic microflora. Antimicrob Agents Ch 1989; 33: 204–8. 84. Pletz MWR, Rau M, Bulitta J et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Ch 2004; 48: 3765–72.
RkJQdWJsaXNoZXIy MTk4NDMw